Keyword: Actelion Pharmaceuticals
The CFDA aims to speed orphan meds to market with conditional OKs for drugs approved abroad, even without any in-China trial data.
The European Medicines Agency, after a review, said Actelion’s new pulmonary arterial hypertension med Uptravi is in the clear.
It’s no secret that Sanofi has struggled of late at the dealmaking table. But why? The deal prospectus from former target Actelion buyer J&J offers some clues.
J&J is counting on new buy Actelion’s pulmonary arterial hypertension meds to provide a top-line boost. But one of them may have just hit a safety snag.
Johnson & Johnson is facing a variety of strong headwinds across its business lines, and in Q4, its newer pharma products couldn't bail the company out.
Could Actelion's $26 billion-plus deal talks with J&J fall through, now that its PAH drug Opsumit has fallen short in a study designed to grow its market? Not likely, analysts said Monday.